Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors

Overview

Journal Cancer Epidemiol Biomarkers Prev

Specialties Biochemistry
Oncology
Public Health

Date 2024 Dec 5

PMID 39636161

Authors

Shyam Patel

Mandana Khalili

Amit G Singal

Paulo S Pinheiro

Patricia D Jones

Rebecca G Kim

Vishwajit Kode

Anna Thiemann

Wei Zhang

Ramsey Cheung

Robert J Wong

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) disproportionately affects racial/ethnic minorities. We evaluated the impact of income and geography on racial/ethnic disparities across the HCC care cascade in the United States.

Methods: Using NCI registry data spanning 2000 to 2020, adults with HCC were evaluated to determine race/ethnicity-specific differences in tumor stage at diagnosis, delays and gaps in treatment, and survival. Adjusted regression models evaluated predictors of HCC outcomes.

Results: Among 112,389 adults with HCC, cohort characteristics were as follows: 49.8% non-Hispanic White (NHW), 12.0% African American(AA), 20.5% Hispanic, 16.5% Asian/Pacific Islander, and 1.1% American Indian/Alaska Native. Compared with NHW patients, AA patients had lower odds of localized-stage HCC at diagnosis [adjusted odds ratio (aOR), 0.84], lower odds of HCC treatment receipt (aOR, 0.77), greater odds of treatment delays (aOR, 1.12), and significantly greater risk of death [adjusted hazards ratio (aHR), 1.10]. Compared with NHW patients from large metro areas, AA patients from large metro areas had 8% higher mortality risk (aHR, 1.08), whereas AA patients from small-medium metro areas had 17% higher mortality risk (aHR, 1.17; all P < 0.05).

Conclusions: Among a population-based cohort of US adults with HCC, significant race/ethnicity-specific disparities across the HCC care continuum were observed. Lower household income and more rural geography among racial/ethnic minorities are also associated with disparities in HCC outcomes, particularly among AA patients.

Impact: Our study shows that lower income and less urban/more rural geography among racial/ethnic minorities are also associated with disparities in HCC outcomes, particularly among AA patients with HCC. This contextualizes the complex relationship between sociodemographic factors and HCC outcomes through an intersectional lens.

References

Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D . Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011; 364(23):2199-207. PMC: 3820419. DOI: 10.1056/NEJMoa1009370. View

Rao A, Rich N, Marrero J, Yopp A, Singal A . Diagnostic and Therapeutic Delays in Patients With Hepatocellular Carcinoma. J Natl Compr Canc Netw. 2021; 19(9):1063-1071. DOI: 10.6004/jnccn.2020.7689. View

Flores Y, Datta G, Yang L, Corona E, Devineni D, Glenn B . Disparities in Hepatocellular Carcinoma Incidence, Stage, and Survival: A Large Population-Based Study. Cancer Epidemiol Biomarkers Prev. 2021; 30(6):1193-1199. PMC: 8172467. DOI: 10.1158/1055-9965.EPI-20-1088. View

Hu D, Xing J, Tohme R, Liao Y, Pollack H, Ward J . Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009-2010. Hepatology. 2013; 58(3):856-62. DOI: 10.1002/hep.26286. View

Chayanupatkul M, Omino R, Mittal S, Kramer J, Richardson P, Thrift A . Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2016; 66(2):355-362. DOI: 10.1016/j.jhep.2016.09.013. View

Wong R, Brosgart C, Welch S, Block T, Chen M, Cohen C . An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States. Hepatology. 2021; 74(2):607-626. PMC: 8453838. DOI: 10.1002/hep.31782. View

Khalili M, Guy J, Yu A, Li A, Diamond-Smith N, Stewart S . Hepatitis B and hepatocellular carcinoma screening among Asian Americans: survey of safety net healthcare providers. Dig Dis Sci. 2010; 56(5):1516-23. PMC: 3082048. DOI: 10.1007/s10620-010-1439-3. View

Rich N, Carr C, Yopp A, Marrero J, Singal A . Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2021; 20(2):e267-e288. PMC: 8243558. DOI: 10.1016/j.cgh.2020.12.029. View

Choi H, Kim S, Shum D, Huang C, Shui A, Fox R . Assessing Adherence to US LI-RADS Follow-up Recommendations in Vulnerable Patients Undergoing Hepatocellular Carcinoma Surveillance. Radiol Imaging Cancer. 2024; 6(1):e230118. PMC: 10825700. DOI: 10.1148/rycan.230118. View

10.

Younossi Z, Stepanova M, Ong J, Jacobson I, Bugianesi E, Duseja A . Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol. 2018; 17(4):748-755.e3. DOI: 10.1016/j.cgh.2018.05.057. View

11.

Han J, Wang B, Liu W, Wang S, Chen R, Chen M . Declining disease burden of HCC in the United States, 1992-2017: A population-based analysis. Hepatology. 2022; 76(3):576-588. DOI: 10.1002/hep.32355. View

12.

Kim N, Cravero A, VoPham T, Vutien P, Carr R, Issaka R . Addressing racial and ethnic disparities in US liver cancer care. Hepatol Commun. 2023; 7(7). PMC: 10289716. DOI: 10.1097/HC9.0000000000000190. View

13.

Alvidrez J, Castille D, Laude-Sharp M, Rosario A, Tabor D . The National Institute on Minority Health and Health Disparities Research Framework. Am J Public Health. 2019; 109(S1):S16-S20. PMC: 6356129. DOI: 10.2105/AJPH.2018.304883. View

14.

Singal A, Lok A, Feng Z, Kanwal F, Parikh N . Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clin Gastroenterol Hepatol. 2020; 20(1):9-18. PMC: 8287785. DOI: 10.1016/j.cgh.2020.09.036. View

15.

Ala A, Wilder J, Jonassaint N, Coffin C, Brady C, Reynolds A . COVID-19 and the Uncovering of Health Care Disparities in the United States, United Kingdom and Canada: Call to Action. Hepatol Commun. 2021; 5(10):1791-1800. PMC: 8426700. DOI: 10.1002/hep4.1790. View

16.

Wong R, Kim D, Ahmed A, Singal A . Patients with hepatocellular carcinoma from more rural and lower-income households have more advanced tumor stage at diagnosis and significantly higher mortality. Cancer. 2020; 127(1):45-55. DOI: 10.1002/cncr.33211. View

17.

Pham C, Fong T, Zhang J, Liu L . Striking Racial/Ethnic Disparities in Liver Cancer Incidence Rates and Temporal Trends in California, 1988-2012. J Natl Cancer Inst. 2018; 110(11):1259-1269. PMC: 7191878. DOI: 10.1093/jnci/djy051. View

18.

Kanwal F, Kramer J, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson P . Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018; 155(6):1828-1837.e2. PMC: 6279617. DOI: 10.1053/j.gastro.2018.08.024. View

19.

Kim N, Rozenberg-Ben-Dror K, Jacob D, Berry K, Ioannou G . The COVID-19 Pandemic Highlights Opportunities to Improve Hepatocellular Carcinoma Screening and Diagnosis in a National Health System. Am J Gastroenterol. 2022; 117(4):678-684. PMC: 8976743. DOI: 10.14309/ajg.0000000000001615. View

20.

Wegermann K, Wilder J, Parish A, Niedzwiecki D, Gellad Z, Muir A . Racial and Socioeconomic Disparities in Utilization of Telehealth in Patients with Liver Disease During COVID-19. Dig Dis Sci. 2021; 67(1):93-99. PMC: 7842167. DOI: 10.1007/s10620-021-06842-5. View